Results 11 to 20 of about 3,308,144 (197)

ADAMTS-13 gene expression in antiphospholipid syndrome

Turkish Journal of Hematology, 2011
OBJECTIVE: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent thrombosis and fetal mortality. Thrombotic microangiopathy (TMA) is an important histological finding in catastrophic APS (CAPS) and in APS patients with ...
Veysel Sabri Hançer, Reyhan Diz Küçükkaya, Ayşegül Topal Sarıkaya   +2 more
doaj   +6 more sources

Thrombotic thrombocytopenic purpura with decreased level of ADAMTS-13 activity and increased level of ADAMTS-13 inhibitor in an adolescent [PDF]

Korean Journal of Pediatrics, 2010
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy characterized by endothelial cell damage, resulting in microangiopathic hemolytic anemia, thrombocytopenia, and various degrees of neurological and renal impairment caused by ...
Eun Mi Yang, Dong Kyun Han, Hee Jo Baek, Young Ok Kim, Myung Geun Shin, Hoon Kook, Tai Ju Hwang   +6 more
doaj   +3 more sources

ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies [PDF]

Rambam Maimonides Medical Journal, 2014
Thrombotic microangiopathies (TMAs) comprise a group of distinct disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombosis.
Galit Sarig
doaj   +4 more sources

Plasma Levels of ADAMTS-13 Antigen, ADAMTS-13 Inhibitor, ADAMTS-13 Activity, and Von Willebrand Factor in Patients with Behçet's Disease. [PDF]

Mediterr J Rheumatol
Behçet's Disease (BD) is characterised by recurrent aphthous oral and genital ulcers. Vascular involvement is one of the poor prognostic factors. Previously, von Willebrand Factor (VWF) has been detected higher in BD compared with healthy controls. We hypothesised that decreased activity or increased inhibitor levels of ADAMTS-13 may cause increased ...
Karasu U, Erkek M, Ulutaş F, Demiray A, Çimen Y, Kaymaz S, Açıkbaş İ, Şenol H, Çobankara V.   +8 more
europepmc   +4 more sources

ADAMTS-13 and bleeding phenotype in von Willebrand disease. [PDF]

Res Pract Thromb Haemost, 2020
The bleeding phenotype of von Willebrand disease (VWD) varies highly between patients and can only partly be explained by von Willebrand factor (VWF) parameters. By cleaving large VWF multimers into smaller, less active multimers, ADAMTS-13 is an important regulator of VWF activity.
Boender J, Nederlof A, Meijer K, Mauser-Bunschoten EP, Cnossen MH, Fijnvandraat K, van der Bom JG, de Meris J, Laros-van Gorkom BAP, van Galen KPM, Eikenboom J, de Maat MPM, Leebeek FWG, WiN Study Group.   +13 more
europepmc   +14 more sources

Further characterization of ADAMTS‐13 inactivation by thrombin [PDF]

Journal of Thrombosis and Haemostasis, 2007
The multimeric size and platelet-tethering function of von Willebrand factor (VWF) are modulated by the plasma metalloprotease, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS-13). In vitro ADAMTS-13 is susceptible to proteolytic inactivation by thrombin.In this study, we aimed to characterize the inactivation ...
Lam, JK, Chion, CKNK, Zanardelli, S, Lane, DA, Crawley, JTB   +4 more
openaire   +5 more sources

ADAMTS‐13 glycans and conformation‐dependent activity [PDF]

Journal of Thrombosis and Haemostasis, 2017
Essentials The impact of N-linked glycosylation on ADAMTS-13 function has not been fully explored. The activity of glycan modified ADAMTS-13 was investigated under static and shear stress conditions. Terminal sialic acid on the metalloprotease domain glycans are important for ADAMTS-13 activity.
Nowak, AA, O'Brien, HER, Henne, P, Doerr, A, Vanhoorelbeke, K, Laffan, MA, McKinnon, TAJ   +6 more
openaire   +5 more sources

Therapeutic application of recombinant human ADAMTS-13 improves shock reversal and coagulation status in a trauma hemorrhage and transfusion rat model [PDF]

Intensive Care Medicine Experimental, 2020
Introduction In hemorrhaging trauma patients, the endothelium is activated, resulting in excessive endothelial synthesis of von Willebrand Factor (vWF), which may enhance micro-thrombi formation, resulting in obstruction of the microcirculation and ...
Mathijs R. Wirtz, Daan P. van den Brink, Joris J. T. H. Roelofs, J. Carel Goslings, Nicole P. Juffermans   +4 more
doaj   +2 more sources

Determination of vWF, ADAMTS-13 and Thrombospondin-1 in Venous Thromboembolism and Relating Them to the Presence of Factor V Leiden Mutation [PDF]

Clinical and Applied Thrombosis/Hemostasis
Thrombophilia in venous thromboembolism (VTE) is multifactorial. Von Willebrand factor (vWF) plays a major role in primary hemostasis. While elevated vWF levels are well documented in VTE, findings related to its cleaving protease (ADAMTS-13) are ...
Anwar Al-Awadhi PhD, Rajaa Marouf MBBch, DCP, FRCPath, Mehrez M. Jadaon MS, Mohammad M. Al-Awadhy MD   +3 more
doaj   +2 more sources

Prophylactic use of recombinant ADAMTS-13 during pregnancy for congenital thrombotic thrombocytopenic purpura [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Congenital thrombotic thrombocytopenic purpura (cTTP) related to ADAMTS-13 deficiency is associated with a maternal risk of death of 10% and a risk of fetal loss greater than 50% without treatment.
Éloïse Colliou, Agnès Ribes, Clotilde Gaible, Mathilde Marlas, David Ribes, Isabelle Labadens, Paul Guerby, Stanislas Faguer   +7 more
doaj   +2 more sources